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Abstract
Since the diagnostic characteristics of the Check-KPC ESBL
microarray as a conﬁrmation test on isolates obtained in a rou-
tine clinical setting have not been determined, we evaluated the
microarray in a random selection of 346 clinical isolates with a
positive ESBL screen test (MIC >1 mg/L for cefotaxime or ceft-
azidime or an ESBL alarm from the Phoenix or Vitek-2 expert
system) collected from 31 clinical microbiology laboratories in
the Netherlands in 2009. Using sequencing as the reference
method the sensitivity of the microarray was 97% (237/245), the
speciﬁcity 98% (97/99), the positive predictive value 99% (237/
239) and the negative predictive value 92% (97/105).
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Worldwide, the prevalence of extended-spectrum b-lacta-
mases (ESBLs) is increasing at an alarming rate [1]. For infec-
tion control precautions and the choice of adequate
antibiotic therapy, accurate and rapid detection of ESBLs is
important.
In Enterobacteriaceae, the most prevalent ESBL gene fami-
lies are CTX-M, TEM and SHV [1]. For rapid detection of
those ESBL families, a microarray system has been developed
(Check-KPC ESBL, Check-Points B.V., Wageningen, the Neth-
erlands) [2]. This system uses ligation-mediated ampliﬁcation,
combined with detection of ampliﬁed products on a micro-
array to detect the various CTX-M groups (CTX-M group 1,
2, 9, or combined 8/25) and the ESBL-associated single-nucleo-
tide polymorphisms (SNPs) in TEM and SHV variants. The
assay can not provide a Lahey type number for TEM and SHV
genes (e.g. TEM-6 or SHV-2), but reports to which group they
belong. Compared with phenotypic detection methods, this
array system is faster (obtaining results within one working
day) and provides information on the (combination of) TEM,
SHV or CTX-M groups present, which may be used for epide-
miological or infection control purposes.
Evaluation of this microarray has been performed on col-
lections of isolates expressing a wide variety of b-lactamase
genes [2–4]. High sensitivities (95–100%) and speciﬁcities
(96–100%) were found in these studies. The aim of this study
was to determine the accuracy of the Check-KPC ESBL
microarray as a conﬁrmatory test of ESBLs in the routine
laboratory setting (i.e. on randomly selected clinical isolates
with a positive ESBL screen test). Therefore 346 clinical iso-
lates collected in a national ESBL surveillance study in the
Netherlands were included. In this survey, 31 clinical micro-
biology laboratories collected all Escherichia coli, Klebsiella
pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Entero-
bacter spp. isolates with a positive ESBL screen test according
to the national guidelines (MIC >1 mg/L for cefotaxime or
ceftazidime or an ESBL alarm from the Phoenix or Vitek-2
expert system) from 1 February until 1 May 2009 (http://
www.nvmm.nl/richtlijnen/esbl-screening-en-conﬁrmatie). Of
the 1418 collected isolates, the ﬁrst 25 non-repeat isolates
(one per patient) per participating laboratory were selected
for genotypic analysis, resulting in a collection of 692 isolates.
The accuracy of the microarray was evaluated on a com-
puter-generated random sample of 50% of those isolates
(n = 346). There were no signiﬁcant differences between the
species distribution in the random sample and the total col-
lection. As a reference test, we used the presence of ESBL
genes determined by PCR and DNA sequencing on the same
DNA batch as used for the microarray [2]. In case of pres-
ence of multiple TEM- and SHV-alleles, base calling for both
alleles at positions in the sequence chromatogram that
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showed double peaks in the forward and reversed strand
was resolved manually.
Microarray analysis was performed according to the
instructions of the manufacturer, and interpreted using soft-
ware version 20090508T164015R74 (Check-Points). DNA
isolation was performed using the Ultraclean Microbial
DNA Isolation kit (Mo Bio Laboratories Inc., Carlsbad, CA,
USA) according to the instructions of the manufacturer. In
the case of a positive ESBL phenotype according to the par-
ticipating laboratory (conﬁrmation was performed according
to the national guidelines using ESBL Etest (BioMe´rieux,
Marcy l’Etoile, France) or combidisks with ceftazidime, cefo-
taxime and/or cefepime with and without clavulanic acid) and
an ESBL-negative result of PCR and DNA sequencing for
CTX-M, TEM and SHV ESBL genes, additional PCRs were
performed to detect the presence of rare ESBL families such
as PER, GES and VEB b-lactamase genes [5].
Statistical analyses were performed using SPSS 15.0 (IBM
Inc., Armonk, NY, USA) and Microsoft Excel 2003 (Micro-
soft, Redmond, WA, USA).
Two of the 346 included isolates were excluded from
analysis because DNA sequence results could not be
obtained. Of the remaining 344 isolates, 75% were E. coli
(n = 257), 10% K. pneumoniae (n = 35), 10% Enterobacter cloa-
cae (n = 33), 3% P. mirabilis (n = 10) and 3% K. oxytoca
(n = 9). Based on PCR and sequencing, 245 isolates were
ESBL positive and 99 ESBL negative. Among the 245 ESBL-
positive isolates, in total 255 ESBL genes were identiﬁed: 209
CTX-M, 28 SHV, 16 TEM, 1 GES and 1 PER.
The sensitivity of the microarray for the detection of an
ESBL was 97% (237/245), the speciﬁcity 98% (97/99), the
positive predictive value 99% (237/239) and the negative pre-
dictive value 92% (97/105).
For 95% (228/239) of the isolates with an ESBL positive
microarray result the outcome of the microarray was in
accordance with the sequencing results. In Table 1 the dis-
crepancies in the 11 isolates are speciﬁed.
A false-negative result was obtained in eight isolates. In
six isolates, a CTX-M-1 group ESBL gene was not detected
(four CTX-M-15/28 positive isolates, one CTX-M-1 positive
isolate, and one CTX-M-22 positive isolate), even after
repeating the test. These six represented 3% (6/182) of all
CTX-M-1 group positive isolates in the collection (three
E. coli, two K. pneumoniae and one E. cloacae). This ﬁnding is
in contrast to previous studies, where only failures in the
detection of TEM and SHV genes were reported, and worri-
some because CTX-M-1 group enzymes, especially CTX-M-
15/28, are the most prevalent ESBLs worldwide [6]. The rea-
son is unknown, but may be explained by chance, because
74% (182/245) of the isolates in this collection harboured a
CTX-M-1 group gene, a limited sensitivity of the CTX-M-1
group-speciﬁc probe or a modiﬁcation of the interpretation
software resulting in an alteration of the detection limit. The
other two false negative isolates contained an ESBL gene not
included in the design of the array (one PER and one GES
producing isolate).
A false-positive result was obtained in two isolates con-
taining a TEM-1 gene. However, in these isolates a TEM-17
and a TEM-19 group ESBL gene were identiﬁed by the array
next to a non-ESBL TEM, and both had an ESBL-positive phe-
notype as determined by ESBL Etest. Therefore, these false-
positive results may be explained by the limitation of using







Isolates with discrepant results
n (%) Outcome sequencinga Outcome microarray
Negative (99) 97 (98) 2 (2) 1 TEM-1 (non-ESBL) 1 TEM-17 group (ESBL)
1 TEM-1 (non-ESBL) 1 TEM-19 group (ESBL)
CTX-M-family (199) 190 (95) 9 (5) 4 CTX-M 15/28 (CTX-M-1 group) 4 Negative
1 CTX-M-1 (CTX-M-1 group) 1 Negative
1 CTX-M-22 (CTX-M-1 group) 1 Negative
1 CTX-M-65 (CTX-M-9 group) 1 CTX-M-1 group
1 CTX-M-15/28 (CTX-M-1 group) 1 CTX-M-1 group, CTX-M-8/25 group
1 CTX-M-15/28, TEM-1 (CTX-M-1 group, TEM non-ESBL)b 1 CTX-M-1 group, TEM-19 group
SHV-family (20) 18 (90) 2 (10) 1 SHV-12 (SHV-4 group) 1 SHV-2 group
1 SHV-12 (SHV-4 group) 1 SHV-4 group, CTX-M-9 group
TEM-family (14) 13 (93) 1 (7) 1 TEM-19 (TEM-19 group) 1 TEM-3 group
Combination of genes (10) 7 (70) 3 (30) 1 CTX-M-1, SHV-12 (CTX-M-1 group, SHV-4 group) 1 CTX-M-1 group
1 SHV-12, TEM-25 (SHV-4 group, TEM-19 group) 1 SHV-31 group, TEM-19 group
1 CTX-M-15/28, SHV-12 (CTX-M-1 group, SHV-4 group) 1 CTX-M-1 group, SHV-2 group
Other ESBL genes (2) 0 (0) 2 (100) 1 PER-5 1 Negative
1 GES-1 1 Negative
aBetween brackets the array group to which the gene belongs is noted.
bBeside the noted CTX-M gene, a TEM ESBL could not be conﬁrmed and only a TEM non-ESBL was found by sequencing.
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an unselective PCR and sequencing as the reference test,
which failed to detect TEM ESBL genes in the presence of
non-ESBL TEM genes, whereas the microarray system uses a
selective ampliﬁcation approach that detects these TEM ESBL
genes accurately. Taking these characteristics of the refer-
ence test into account, the speciﬁcity and positive predictive
value of the microarray would be 100% (99/99 and 237/237)
and the negative predictive value 93% (99/107). There was
one other isolate in which a TEM-19 group ESBL gene was
identiﬁed by the array next to a non-ESBL TEM, while
sequencing only detected a non-ESBL TEM. However, this
discrepancy did not inﬂuence the test characteristics because
the isolate possesses also a CTX-M gene detected by both
array and PCR.
A limitation of the study is that although the microarray
was evaluated on isolates representative of the routine clini-
cal setting the test was performed centrally. However,
because of the simple and straightforward protocol of the
microarray, no problems with the performance are to be
expected in other laboratories. In conclusion, this study
shows that the Check-KPC ESBL microarray is a rapid and
accurate conﬁrmation test for the presence of ESBL genes in
the clinical setting. It may be used if a rapid result is
required, if the phenotypic ESBL conﬁrmation test is non-
conclusive, for species in which phenotypic ESBL detection is
difﬁcult (e.g. K. oxytoca) due to production of other class A
b-lactamases or for infection control purposes (investigating
a plasmid outbreak). Furthermore, the array is a high
throughput diagnostic tool that is particularly well suited for
epidemiological studies when testing a large number of iso-
lates for the presence of ESBL.
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A simple test for the detection of KPC and
metallo-b-lactamase carbapenemase-
producing Pseudomonas aeruginosa isolates
with the use of meropenem disks
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Abstract
We evaluated the ability of the combination disk test (CDT) and
the Modiﬁed Hodge Test (MHT) to discriminate between vari-
ous carbapenemase-producing Pseudomonas aeruginosa isolates
(KPC, n = 36; metallo-b-lactamase (MBL), n = 38) and carbape-
nemase non-producers (n = 75). For the CDT, the optimal
inhibitor concentrations and cut-off values were: 600 lg of
3-aminophenylboronic acid (APB) per disk (an increment of
‡4 mm), 1000 lg of dipicolinic acid (DPA) per disk (an incre-
ment of ‡5 mm) and 3000 lg of cloxacillin per disk (an incre-
ment of ‡3 mm). APB had excellent sensitivity (97%) and
speciﬁcity (97%) for the detection of KPC enzymes. DPA
detected MBL enzymes with a sensitivity and speciﬁcity of 97%
and 81%, respectively. The MHT resulted in a low sensitivity
(78%) and speciﬁcity (57%). The CDT could be very useful in
daily practice to provide fast and reliable detection of KPC and
MBL carbapenemases among P. aeruginosa isolates.
Keywords: 3-Aminophenylboronic acid, carbapenemase, cloxa-
cillin, dipicolinic acid, Pseudomonas aeruginosa
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